Legence LGN 深 沪
等待开盘 08-19 09:30:00 美东时间
63.66
-6.380
-9.11%
华盛通- 最 高68.5863
- 今 开68.03
- 成交量 92.48万股
- 最 低 63.53
- 昨 收 70.04
- 总市值 688.01万
- 52周最高 107.2375
- 市盈率 静 --
- 换手率 0.86%
- 52周最低 26.96
- 委 比 -13.49%
- 总股本 0.00亿
- 历史最高 107.2375
- 量 比 0.58
- 振 幅 7.22%
- 历史最低 26.96
- 每 手 1
- 风险率 18.97%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅167.3%！HC Wainwright上调Tango Therapeutics目标价至68美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Tango Therapeutics"买入"评级，目标价从66美元升至68美元；康托·菲茨杰拉德：维持Duos Technologies Group"超配"评级，目标价从26美元升至27美元
今天 08:37
Legence Corp. Appoints Independent Finance Veteran to Board
An update from Legence Corp. Class A ( ($LGN) ) is now available. On August 18,...
今天 04:59
美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
美股夜盘 | ERock大升9.15%，Keel Infrastructure Corp.大升5.70%
ERock大升9.15%；Keel Infrastructure Corp.大升5.70%；Marex Group大升5.21%
08-17 13:01
Legence shares are trading lower after the company reported mixed Q2 financial results.
Legence shares are trading lower after the company reported mixed Q2 financial results.
08-13 23:15
Legence Q2 EPS $0.17 Misses $0.33 Estimate, Sales $1.260B Beat $1.074B Estimate
Legence (NASDAQ:LGN) reported quarterly earnings of $0.17 per share which missed the analyst consensus estimate of $0.33 by 48.48 percent. The company reported quarterly sales of $1.260 billion which beat the analyst consensus estimate of $1.074 billion by 17.35 percent.
08-13 19:29
Legence Sees Q3 Sales $1.225B-$1.275B vs $1.080B Est
Legence (NASDAQ:LGN) sees Q3 sales of $1.225 billion-$1.275 billion vs $1.080 billion analyst estimate.
08-13 19:02
Legence Raises FY2026 Sales Guidance from $4.100B-$4.300B to $4.700B-$4.800B vs $4.274B Est
Legence (NASDAQ:LGN) raises FY2026 sales outlook from $4.100 billion-$4.300 billion to $4.700 billion-$4.800 billion vs $4.274 billion estimate.
08-13 19:02
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
